Explore the economic and logistical factors driving prescription drug shortages and their impact on global patient care.

The US Food and Drug Administration (FDA) approved or tentatively approved 776 Abbreviated New Drug Applications (ANDAs) for generic drugs in 2021, continuing a steady decline in generic approvals in ...

The U.S. Supreme Court will hear a case that could clarify when generic drug makers are liable for patent infringement tied ...

According to a latest market analysis by Future Market Insights, the global pharmaceutical intermediates market is witnessing ...

Why, nearly 100 years after the discovery of insulin, are no low-priced generic versions available? The complicated answer to that question is explored in a special article published in the March 19 ...

WASHINGTON (AP) — The Food and Drug Administration on Tuesday approved a generic medication for a rare brain disorder, while walking back suggestions by President Donald Trump and other administration ...

Drug shortages increase health expenditures and impede effective patient care. In a 2017 American Hospital Association (AHA) survey of 1,184 US hospitals, 80 percent indicated that shortages ...

CHICAGO - JULY 23: Lipitor tablets sit in a tray at a Pharmacy July 23, 2008 in Chicago, Illinois. Pfizer, the world's biggest drug maker and manufacturer of the cholesterol drug Lipitor, said today ...

Forbes contributors publish independent expert analyses and insights. Sally Pipes is a scholar and think tank CEO who writes on health care. America’s generic drug market is one of our greatest health ...

Generic drugmakers continue to face mounting pressure not only from pricing competition but also from Trump’s push for pharmaceutical import tariffs and the proposed “most-favored-nation” pricing ...

Health Secretary Robert F. Kennedy Jr. found himself defending President Donald Trump‘s drug pricing claims during a tense ...

The U.S. Supreme Court has agreed to hear Hikma Pharmaceuticals USA v. Amarin Pharma, a case that could redefine liability for generic drug makers. The dispute centers on whether Hikma can be held ...